To strengthen the anabolic properties of testosterone, more than 100 synthetic steroid derivatives have been described for human purposes. The anabolic effect promotes protein synthesis, muscle growth and erythropoiesis. In clinical practice, substances with anabolic effect are needed to overcome various catabolic states. However, none of these compounds are devoid of androgenicity. Androgenic and anabolic properties of anabolic steroids cannot be totally separated. Therefore, it is more appropriate to use the term anabolic androgenic steroids (AAS).
Injectable steroids are injected into muscle tissue, not into the veins. They are slowly released from the muscles into the rest of the body, and may be detectable for months after last use. Injectable steroids can be oil-based or water-based. Injectable anabolic steroids which are oil-based have longer half-life than water-based steroids. Both steroid types have much longer half-lives than oral anabolic steroids. And this is proving to be a drawback for injectables as they have high probability of being detected in drug screening since their clearance times tend to be longer than orals. Athletes resolve this problem by using injectable testosterone early in the cycle then switch to orals when approaching the end of the cycle and drug testing is imminent.
Nasal septal perforation, fungal infection of the nose, and disturbances of taste and smell have been reported. Higher doses of mometasone may cause suppression of the body's ability to make its own natural glucocorticoid in the adrenal gland . People with suppression of their adrenal glands (which can be diagnosed by a doctor) would need increased amounts of glucocorticoids, probably by the oral or intravenous route, during periods of high physical stress or acute illness when glucocorticoids are particularly important. Intranasal steroids may cause growth suppression, weaken the immune system, and may increase the risk of glaucoma , and cataracts .